235 related articles for article (PubMed ID: 29529444)
1. Drug Policy in Estonia.
Mägi K; Lepaste M; Szkultecka-Dębek M
Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
[TBL] [Abstract][Full Text] [Related]
2. Drug Policy in Latvia.
Silins J; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
[TBL] [Abstract][Full Text] [Related]
3. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
4. Drug Policy in Croatia.
Culig J; Antolic S; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():27-30. PubMed ID: 29073984
[TBL] [Abstract][Full Text] [Related]
5. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
7. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
8. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
9. Drug Policy in Hungary.
Inotai A; Csanádi M; Harsányi A; Németh B
Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
[TBL] [Abstract][Full Text] [Related]
10. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
Hsu JC; Lu CY
Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
[TBL] [Abstract][Full Text] [Related]
11. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
12. Drug Policy in the Russian Federation.
Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
[TBL] [Abstract][Full Text] [Related]
13. New Drug Reimbursement and Pricing Policy in Taiwan.
Chen GT; Chang SC; Chang CJ
Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
[TBL] [Abstract][Full Text] [Related]
14. Drug Policy in Greece.
Yfantopoulos JN; Chantzaras A
Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
[TBL] [Abstract][Full Text] [Related]
15. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
16. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
Mapelli V; Lucioni C
Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
[TBL] [Abstract][Full Text] [Related]
17. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
18. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
19. Integration of economic appraisal and health care policy in a health insurance system; the Dutch case.
Rutten F; van der Linden JW
Soc Sci Med; 1994 Jun; 38(12):1609-14. PubMed ID: 8047918
[TBL] [Abstract][Full Text] [Related]
20. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
Mahlich J; Sindern J; Suppliet M
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
